Pharmaceutical Technology on MSN7d
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKD
The US Food and Drug Administration (FDA) has approved scPharmaceuticals’ supplemental new drug application (sNDA) for ...
MPR2d
Wearable Furosemide Delivery System Approved for CKD Patients
The Food and Drug Administration (FDA) has expanded the approval of Furoscix® (furosemide injection) to include the treatment of edema in patients with ...
scPharmaceuticals announces FDA approval of Furoscix indication expansion
Pharmaceuticals (SCPH) announced that the FDA has approved the supplemental new drug application for Furoscix to expand the indication to ...
Nasdaq7d
ScPharma: FDA Approves FUROSCIX For Treating Edema In Chronic Kidney Disease Patients
(RTTNews) - scPharmaceuticals Inc. (SCPH) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for FUROSCIX to expand the indication ...
The Pharma Letter5d
The week in pharma: action, reaction and insight – week to March 7
Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...
ETF Daily News4d
scPharmaceuticals (SCPH) to Release Earnings on Wednesday
Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with ...
The Pharma Letter7d
FDA nod for scPharmaceuticals’ Furoscix sNDA
Cardiorenal specialist scPharmaceuticals has won US Food and Drug Administration (FDA) approval for its supplemental New Drug Application (sNDA) for Furoscix (furosemide injection) to expand the ...
Renal & Urology News4d
Wearable Furosemide Delivery System Approved for CKD Patients
Furoscix is expected to be available for CKD patients in April 2025. The Food and Drug Administration (FDA) has expanded the approval of Furoscix ® (furosemide injection) to include the treatment ...